But I dont believe thats been studied in a rigorous way. Rather than developing a dosage off-ramp, other experts argue that these drugs should be treated like any other chronic disease medication
It enhances the secretion of insulin, lowers glucagon secretion, and slows gastric emptying
Aleniglipron is a small molecule that makes for simpler scalability and will likely have reduced COGS allowing for greater price flexibility vs peptide-based therapies
Patients should contact their GP or healthcare team if they experience: Persistent, severe abdominal pain (possible pancreatitis) Signs of hypoglycaemia (sweating, tremor, confusion, palpitations), particularly if taking sitagliptin with sulfonylureas or insulin Persistent blistering skin lesions Facial swelling, difficulty breathing, or severe rash (possible serious allergic reactionseek emergency help) Suspected side effects should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or by searching for MHRA Yellow Card in the Google Play or Apple App Store
MAFLD, metabolic dysfunction-associated fatty liver disease